The effect of blockade of the CD40-CD40L pathway on T and B cell mediated alloreactivity after kidney transplantation

The effect of blockade of the CD40-CD40L pathway on T and B cell mediated alloreactivity after kidney transplantation - Immunologic effects of CFZ533 (iscalimab) - CirrusISubI

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50147

Enrollment

Registered

2019-03-04

Start date

2019-10-16

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

orgaantransplantatie kidney transplantation organ transplantation

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All patients participating in the main trial (MEC 2018-138)

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Number and characteristics of effector and regulatory T-, and B- cells and dendritic cells (DC), T and B cell interaction and cytokine production and effectiveness of CFZ533 to block CD40 expression will be studied. If a renal biopsy is performed in the main study (MEC-2018-138), the cellular infiltrate will also be characterized with additional markers focused on the CD40-CD40L(CD154) axis.	—

Countries

Netherlands

Outcome results